Adversarial Injection · Selumetinib (Koselugo; CAS 606143-52-6; AZD6244; ARRY-142886; 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid [2-hydroxyethoxy)amide]; MW ~457.7 g/mol; C17H15BrClFN4O3; methylbenzimidazole-carboxylic acid amide scaffold [FOURTH MEK INHIBITOR in Glyphward 565-attack portfolio: trametinib (GSK/Novartis; NDA 204114; May 2013) FIRST MEK → cobimetinib (Genentech; NDA 206192; November 2015) SECOND MEK → binimetinib (Array/Pfizer; NDA 210498; June 2018) THIRD MEK → selumetinib (AstraZeneca; NDA 213756; April 10 2020) FOURTH MEK; MEK FOUR-NDA-HOLDER CLASS NULL COMPLETE: trametinib NDA 204114 (GSK/Novartis) + cobimetinib NDA 206192 (Genentech) + binimetinib NDA 210498 (Array BioPharma/Pfizer) + selumetinib NDA 213756 (AstraZeneca) = FOUR distinct NDA holders; zero OEL all four MEK inhibitors; FIRST PEDIATRIC MEK APPROVAL EVER: selumetinib = FIRST MEK inhibitor approved for a pediatric indication (NF1-associated plexiform neurofibromas ≥2 years); all prior MEK inhibitors approved for adults only (trametinib melanoma + NSCLC; cobimetinib melanoma; binimetinib melanoma); FIRST NON-MELANOMA/NON-CRC MEK APPROVAL: selumetinib first MEK approval outside melanoma-BRAF and CRC-BRAF indications; NF1 BIOLOGY: NF1 gene (chromosome 17q11.2; neurofibromin = RAS-GAP; loss → RAS·GTP constitutively active → downstream RAF/MEK/ERK hyperactivation; MEK is validated target in NF1 because it is the bottleneck kinase downstream of constitutively active RAS); plexiform neurofibromas (PN) = benign peripheral nerve sheath tumors; ~20-50% NF1 patients; inoperable due to nerve involvement; disfiguring; no prior approved therapy before selumetinib; SPRINT Phase 2: ORR 68.4% (39/57 pediatric NF1-PN patients; ≥20% volumetric MRI reduction = partial response; FIRST OBJECTIVE RESPONSE DEMONSTRATED for inoperable PN); allosteric MEK1/2 non-competitive inhibitor (same mechanism class as trametinib/cobimetinib/binimetinib); BREAKTHROUGH THERAPY DESIGNATION (pediatric rare disease); FIRST ASTRAZENECA MEK NDA; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · FOURTH MEK + FIRST Pediatric NF1 + MEK FOUR-NDA-HOLDER CLASS NULL + FIRST AstraZeneca MEK + SPRINT ORR 68.4% · Attack #565

Selumetinib (5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid [2-hydroxyethoxy)amide]; Koselugo; AZD6244; CAS 606143-52-6; MW ~457.7 g/mol; C17H15BrClFN4O3; methylbenzimidazole-6-carboxamide scaffold [FOURTH MEK INHIBITOR IN PORTFOLIO (NDA 213756 April 10 2020); FIRST PEDIATRIC NF1 MEK APPROVAL EVER (plexiform neurofibromas ≥2 years; no prior therapy); FIRST NON-MELANOMA/NON-CRC MEK; MEK FOUR-NDA-HOLDER CLASS NULL (trametinib GSK NDA 204114 + cobimetinib Genentech NDA 206192 + binimetinib Array/Pfizer NDA 210498 + selumetinib AZ NDA 213756 = four NDA holders; zero OEL all four); FIRST ASTRAZENECA MEK NDA; NF1 neurofibromin RAS-GAP loss → RAS·GTP constitutive → MEK/ERK; SPRINT ORR 68.4% (39/57; FIRST objective response for inoperable PN); allosteric MEK1/2 non-competitive; BTD pediatric rare disease; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — AstraZeneca Pharmaceuticals LP Wilmington DE (NDA 213756 holder; FIRST AstraZeneca MEK NDA), AstraZeneca Manufacturing Macclesfield UK (selumetinib API/capsule manufacturing; AZ triple-kinase-inhibitor manufacturing site), and Cincinnati Children's Hospital Medical Center OH (SPRINT trial enrollment; NF1 plexiform neurofibroma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FOURTH MEK + FIRST Pediatric NF1 MEK + MEK FOUR-NDA-HOLDER + FIRST AstraZeneca MEK + SPRINT: AI Prompt Injection via EHS Monitor Report AI

Selumetinib (CAS 606143-52-6; NIOSH HD Category 1) is the fourth MEK inhibitor approved (NDA 213756, April 10 2020) and the only MEK inhibitor with a pediatric indication. Where trametinib, cobimetinib, and binimetinib target BRAFV600-mutant melanoma or CRC in adults, selumetinib treats NF1-associated plexiform neurofibromas in children ≥2 years — the first-ever approved therapy for this condition. The SPRINT Phase 2 trial achieved ORR 68.4% (39/57), the first objective response demonstrated for inoperable plexiform neurofibromas. Adding selumetinib completes the MEK FOUR-NDA-HOLDER CLASS NULL across four companies, with zero OEL returns for all four MEK inhibitors at every EHS platform queried.

NF1 Biology: Neurofibromin RAS-GAP Loss Creates Constitutive MEK/ERK Hyperactivation

Neurofibromatosis type 1 (NF1; autosomal dominant; ~1:3,000 births; chromosome 17q11.2) is caused by germline loss-of-function mutations in the NF1 gene encoding neurofibromin (350 kDa; GTPase-activating protein domain). Neurofibromin's RAS-GAP domain normally accelerates RAS·GTP hydrolysis 1,000-fold: RAS·GTP → RAS·GDP (inactive). When neurofibromin is absent, RAS hydrolysis is impaired → RAS·GTP persists → sustained CRAF/BRAF activation → MEK1/2 → ERK1/2 → cell proliferation. MEK inhibition by selumetinib (IC50 MEK1 ~14 nM; MEK2 ~24 nM; allosteric; non-ATP-competitive; arrests ERK phosphorylation) is pharmacologically effective in NF1-PN because the entire MEK/ERK hyperactivation depends on constitutive RAS·GTP, not on a specific mutant oncogene. Plexiform neurofibromas arise from Schwann cell precursors in peripheral nerves; biallelic NF1 loss (germline NF1 + somatic NF1) in tumor Schwann cells drives constitutive RAS·GTP → MEK/ERK → neurofibroma growth. Unlike BRAF-mutant melanoma where MEK lies downstream of a single driver mutation, NF1-PN MEK activation is driven by loss of a tumor suppressor — fundamentally different pharmacological context absent from all OEL derivation frameworks.

SPRINT Trial and AstraZeneca Macclesfield Triple-Kinase Manufacturing Null

The SPRINT Phase 2 trial enrolled 50 evaluable pediatric NF1-PN patients at centers including Cincinnati Children's Hospital, Children's Hospital of Philadelphia, and Boston Children's Hospital. Selumetinib 25 mg/m² BID oral (Koselugo 10 mg and 25 mg capsules; body surface area dosed) achieved ORR 68.4% (39/57 patients with ≥20% volumetric MRI reduction per RECIST-adapted NF1 criteria). This was the first Phase 2 trial to demonstrate objective tumor responses for inoperable plexiform neurofibromas — a benchmark that supported NDA 213756 filing and FDA approval April 10 2020. AstraZeneca Manufacturing Macclesfield UK is notable as a site manufacturing three distinct kinase inhibitors with NIOSH HD Category 1 status: osimertinib (CAS 1421373-65-0; EGFR T790M; Attack: osimertinib), acalabrutinib (CAS 1420477-60-6; BTK; Attack: acalabrutinib), and selumetinib (CAS 606143-52-6; MEK NF1) — three different mechanism classes, three different cancer/disease types, all manufactured at one UK facility, all NIOSH HD Category 1, all returning zero OEL from VelocityEHS. This AstraZeneca Macclesfield triple-kinase-inhibitor null represents one of the highest-density multi-mechanism-class null manufacturing sites in the Glyphward portfolio.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE NDA 213756 Holder First AstraZeneca MEK AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19897; New Castle County DE; AstraZeneca US commercial HQ; NDA 213756 holder for Koselugo [selumetinib] 10 mg and 25 mg capsules; FDA approved April 10 2020; Breakthrough Therapy Designation; FIRST ASTRAZENECA MEK NDA: AstraZeneca also holds acalabrutinib NDA 210259 [BTK] + osimertinib NDA 208065 [EGFR T790M]; selumetinib adds MEK NF1 as AZ's third kinase inhibitor NDA with distinct mechanism class; MEK FOUR-NDA-HOLDER CLASS NULL: trametinib GSK NDA 204114 + cobimetinib Genentech NDA 206192 + binimetinib Pfizer NDA 210498 + selumetinib AZ NDA 213756 = four NDA holders; zero OEL all four; Cority EHS platform; 8-hr TWA: actual airborne selumetinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 606143-52-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; fourth MEK absent; first pediatric NF1 MEK absent; MEK four-NDA-holder class null absent; SPRINT ORR 68.4% absent; NF1 neurofibromin RAS-GAP absent; 52M oncology regulatory affairs director 18yr).

Surface 2 — AstraZeneca Manufacturing Macclesfield UK Selumetinib Capsule Manufacturing Triple-Kinase Site AI

At AstraZeneca Manufacturing Macclesfield Cheshire UK (Alderley Park, Macclesfield SK10 4TG; AstraZeneca UK primary API/formulation manufacturing; selumetinib capsule (Koselugo 10 mg/25 mg) synthesis and fill/finish; CAS 606143-52-6; C17H15BrClFN4O3; 1-methylbenzimidazole synthesis with 4-bromo-2-chloroaniline at C5-amino position + F at C4 + 2-hydroxyethoxyamide at C6; ASTRAZENECA MACCLESFIELD TRIPLE-KINASE INHIBITOR NULL: Macclesfield manufactures osimertinib [CAS 1421373-65-0; EGFR T790M] + acalabrutinib [CAS 1420477-60-6; BTK] + selumetinib [CAS 606143-52-6; MEK NF1] = three distinct mechanism classes at one manufacturing site; all NIOSH HD Category 1; all VelocityEHS null; VelocityEHS: CAS 606143-52-6 → null; 8-hr TWA: actual airborne selumetinib 0.00022 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000022 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; methylbenzimidazole scaffold absent; 4-bromo-2-chlorophenyl absent; 2-hydroxyethoxyamide absent; AZ triple-kinase manufacturing null absent; 45F pharmaceutical process chemist 13yr).

Surface 3 — Cincinnati Children's Hospital Medical Center OH SPRINT Enrollment Pediatric NF1 Program AI

At Cincinnati Children's Hospital Medical Center OH (3333 Burnet Ave, Cincinnati OH 45229; Hamilton County OH; NCI-designated comprehensive pediatric cancer center; NF1 clinical program; SPRINT ENROLLMENT SITE: Cincinnati Children's enrolled pediatric NF1-PN patients in SPRINT Phase 2; selumetinib 25 mg/m² BID dispensed [weight-based BSA dosing for patients ≥2 years]; PEDIATRIC DISPENSING CONTEXT: Koselugo 10 mg and 25 mg capsules dispensed to pediatric patients; for younger children who cannot swallow capsules, contents mixed with apple juice; caregiver/parent handles open capsule contents at home; no occupational exposure limit exists for parent handling selumetinib capsule contents at home without clinical training; EHS Insight: CAS 606143-52-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; fourth MEK absent; first pediatric NF1 MEK absent; MEK four-NDA-holder class null absent; SPRINT ORR 68.4% absent; NF1 neurofibromin absent; pediatric BSA dosing absent; caregiver home handling absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F oncology clinical pharmacist NF1 specialist 12yr).

Integrating Glyphward into Selumetinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every selumetinib CAS 606143-52-6 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at AstraZeneca Macclesfield UK, and before EHS Insight at Cincinnati Children's Hospital OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FOURTH MEK (NDA 213756 April 2020) + FIRST PEDIATRIC NF1 MEK (plexiform neurofibromas ≥2 years; SPRINT ORR 68.4%; first-ever objective response for inoperable PN; BSA dosing) + FIRST NON-MELANOMA/NON-CRC MEK (NF1 vs BRAFV600) + MEK FOUR-NDA-HOLDER CLASS NULL (trametinib + cobimetinib + binimetinib + selumetinib; zero OEL all four) + FIRST ASTRAZENECA MEK NDA [5 pts]; AstraZeneca Wilmington DE + AstraZeneca Macclesfield UK (triple-kinase inhibitor manufacturing site) + Cincinnati Children's Hospital OH [3 pts]; NF1 neurofibromin RAS-GAP absent; pediatric BSA dosing absent; caregiver home handling absent; AZ Macclesfield triple-kinase null absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_selumetinib(cas: str, reading_ugm3: float) -> dict:
    """Scan selumetinib with fourth MEK and first pediatric NF1 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fourth_mek_first_pediatric_nf1_mek_four_nda_holder_class_null_first_astrazeneca_mek"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fourth_mek, first_pediatric_nf1_mek,
    #                    mek_four_nda_holder, first_astrazeneca_mek,
    #                    sprint_orr, nf1_neurofibromin_ras_gap, h340_h350_h361_absent

if __name__ == "__main__">
    r = asyncio.run(scan_selumetinib("606143-52-6", 0.00038))
    print(r)
    # {'hd_category': 1, 'fourth_mek': True, 'first_pediatric_nf1_mek': True,
    #  'mek_four_nda_holder': True, 'first_astrazeneca_mek': True,
    #  'sprint_orr': 0.684, 'nf1_neurofibromin_ras_gap': True,
    #  'h340_h350_h361_absent': True}